Under terms of the deal, Novo Nordisk will obtain global rights to develop, manufacture, and commercialize LX9851 for obesity ...

The high-stakes nature of cancer care, coupled with rapid scientific advancements, increasing payer and regulatory pressures, ...

In a world riddled with misinformation online, trust-building between healthcare providers (HCPs) and their patients has ...

Marcel Botha, CEO of 10XBeta, discusses shortcomings in the US's emergency plans for rapid innovation and manufacturing ...

As part of the Fast Track designation, Sanofi is set to launch a Phase I/II trial to evaluate the immunogenicity and safety of its novel mRNA vaccine in preventing chlamydia.